Alpha-Synuclein as a pathological link between chronic traumatic brain injury and parkinson's disease

Journal of Cellular Physiology

Volumn 230, Issue 5, 2015, Pages 1024-1032

  Acosta, Sandra A ^a   Tajiri, Naoki ^a   de la Pena, Ike ^a   Bastawrous, Marina ^a   Sanberg, Paul R ^a,b   Kaneko, Yuji ^a   Borlongan, Cesar V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TYROSINE 3 MONOOXYGENASE; HLA ANTIGEN CLASS 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL SURVIVAL; CEREBRAL PEDUNCLE; CHRONIC BRAIN DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MALE; MICROGLIA; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; TRAUMATIC BRAIN INJURY; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; BRAIN INJURY; CHRONIC DISEASE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN INJURIES; CEREBRAL PEDUNCLE; CHRONIC DISEASE; DOPAMINERGIC NEURONS; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICROGLIA; MODELS, BIOLOGICAL; PARKINSON DISEASE; PARS COMPACTA; RATS, SPRAGUE-DAWLEY; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 84921646863     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24830     Document Type: Article

References (59)

1. Abdul-Muneer PM, Schuetz H, Wang F, Skotak M, Jones J, Gorantla S, Zimmerman MC, Chandra N, Haorah J. 2013. Induction of oxidative and nitrosative damage leads to cerebrovascular inflammation in an animal model of mild traumatic brain injury induced by primary blast. Free Radic Biol Med 60:282-291.
2. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252.
3. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Grimmig B, Diamond DM, Sanberg PR, Bickford PC, Kaneko Y, Borlongan CV. 2013. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PloS One 8:e53376.
4. Amstrong RA. 2003. Quantifying the pathology of neurodegerative disorders: Quantitative measurements, sampling strategies and data analysis. Histopathology 42:521-529.
5. Amstrong RA, Kotzbauer PT, Perlmutter JS, Cambell MC, Hurth KM, Schmidt RE, Cairns NJ. 2014. A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. J Neural Transm 121:171-181.
6. Auluck PK, Caraveo G, Lindquist S. 2010. Alpha-Synuclein: Membrane interactions and toxicity in Parkinson's disease. Ann Rev Cell Dev Biol 26:211-233.
7. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. 2003. Head trauma preceding PD: A case-control study. Neurology 60:1610-1615.
8. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. 2010. Alpha synuclein promotes SNARE complex assembly in vivo and in vitro. Science 329:1663-1667.
9. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Südhof TC. 2004. Double-knockout mice for alpha- and beta-synucleins: Effect on synaptic functions. Proce Natl Acad Sci USA 101:14966-14971.
10. Chaudhuri KR, Healy DG, Schapira AH. 2006. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 5:235-245.
11. Chauhan NB. 2014. Chronic neurodegenerative consequences of traumatic brain injury. Restorative Neurol Neurosci 32:337-365.
12. Cheng G, Kong RH, Zhang LM, Zhang JN. 2012. Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies. Br J Pharmacol 167:699-719.
13. Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, Williamson RE, Lansbury PT, Jr. 2000b. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann NY Acad Sci 7:42-45.
14. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, Jr. 2000a. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97:571-576.
15. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, McLean PJ. 2011. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J: Off Publ Fed Am Soc Exp Biol 25:326-336.
16. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. 2010. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30:6838-6851.
17. Ettenhofer KS, Abeles N. 2009. The significant of mild traumatic brain injury to cognition and self-reported sympons in long term recovery from injury. J Clin Exp Neuropsychol 31:363-372.
18. Fabrizio KS, Keltner NL. 2010. Traumatic brain injury in operation enduring freedom/operation iraqi freedom: A primer. Nursing Clinics North America 45:569-580, vi.
19. Faul M, Xu L, Wald MM, Coronado VG. 2010. Traumatic brain injury in the United States: Emergency department visits, hospitalizations and deaths. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Injury Prevention and Control.
20. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL. 2012. Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol 123:653-669.
21. Goedert M. 2001. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501.
22. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. 2006. Head injury and Parkinson's disease risk in twins. Ann Neurol 60:65-72.
23. Glover LE, Tajiri N, Lau T, Kaneko Y, van Loveren H, Borlongan CV. 2012. Immediate, but not delayed, microsurgical skull reconstruction exacerbates brain damage in experimental traumatic brain injury model. PloS One 7:e33646.
24. Hutson CB, Lazo CR, Mortazavi F, Giza CC, Hovda D, Chesselet MF. 2011. Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma 28:1783-1801.
25. Jankovic J. 2008. Parkinson's disease: Clinical features and diagnosis. J Neurol, Neurosurg Psychiatr 79:368-376.
26. Jannetta PJ, Whiting DM, Fletcher LH, Hobbs JK, Brillman J, Quigley M, Fukui M, Williams R. 2011. Parkinson's disease: An inquiry into the etiology and treatment. Neurol Int 3:e7.
27. Karantzoulis S, Randolph C. 2013. Modern chronic traumatic encephalopathy in retired athletes: What is the evidence. Neuropsychol Rev 23:350-360.
28. Klein C, Westenberger A. 2012. Genetics of Parkinson's disease. Cold Spring Harbor Perspect Med 2:a008888.
29. Kokjohn TA, Maarouf CL, Daugs ID, Hunter JM, Whiteside CM, Malek-Ahmadi M, Rodriguez E, Kalback W, Jacobson SA, Sabbagh MN, Beach TG, Roher AE. 2013. Neurochemical profile of dementia pugilistica. J Neurotrauma 30:981-997.
30. Levin B, Bhardwaj A. 2014. Chronic traumatic encephalopathy: A critical appraisal. Neurocrit Care 20:334-344.
31. Matsuda W, Matsumura A, Komatsu Y, Yanaka K, Nose T. 2003. Awakenings from persistent vegetative state: Report of three cases with parkinsonism and brain stem lesions on MRI. J Neurol 74:1571-1573.
32. Mayhew TM. 1991. The new stereological methods for interpreting functional morphology from slices of cells and organs. Exp Physiol 76:639-665.
33. Mondello S, Buki A, Italiano D, Jeromin A. 2013. Alpha-synuclein in CSF of patients with severe traumatic brain injury. Neurology 80:1662-1668.
34. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. 2010. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66-79.
35. Ozen LJ, Fernandes MA. 2012. Slowing down after a mild traumatic brain injury: A strategy to improve cognitive task performance. Arch Clin Neuropsychol 27:85-100.
36. Paxinos G, Watson C. 2005. The rat brain in stereotaxic coordinates. 5th ed. San Diego, CA: Academic Press.
37. Prins M, Greco T, Alexander D, Giza CC. 2013. The pathophysiology of traumatic brain injury at a glance. Dis Models Mech 6:1307-1315.
38. Protter D, Lang C, Cooper AA. 2012. Alpha-synuclein and mitochondrial dysfunction: A pathogenic partnership in Parkinson's disease. Parkinson's Dis 2012:829207.
39. Rodrigues TM, Jeronimo-Santos A, Outeiro TF, Sebastiao AM, Diogenes MJ. 2014. Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease. Drugs Aging 31:239-236.
40. Saing T, Dick M, Nelson P, Kim RC, Cribbs DH, Head E. 2012. Frontal cortex neuropathy in dementia pugilistica. J Neurotrauma 29:1054-1070. DOI: 10.1089/neu.2011.1957.
41. Sato H, Kato T, Arawaka S. 2013. The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson's disease: A review of in vivo models. Rev Neurosci 24:115-123.
42. Siebert H, Kahle PJ, Kramer ML, Isik T, Schlüter OM, Schulz-Schaeffer WJ, Brück W. 2010. Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain. J Neurochem 114:1007-1018.
43. Shahaduzzaman Md, Acosta S, Bickford PC, Borlongan CV. 2013. α-Synuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury. Med Hypotheses 81:675-680.
44. Smith C. 2013. Review: The long-term consequences of microglial activation following acute traumatic brain injury. Neuropathol Appl Neurobiol 39:35-44.
45. Smith DH, Johnson VE, Stewart W. 2013. Chronic neuropathologies of single and repetitive TBI: Substrates of dementia. Nat Rev Neurol 9:211-221.
46. Stefanis L. 2012. Alpha-synuclein in Parkinson's disease. Cold Spring Harbor Perspect Med 2:a009399.
47. Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, Hill KJ, Caldwell KA, Bell GW, Fraenkel E, Cooper AA, Caldwell GA, McCaffery JM, Rochet JC, Lindquist S. 2010a. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Models Mech 3:194-208.
48. Su E, Bell MJ, Wisniewski SR, Adelson PD, Janesko-Feldman KL, Salonia R, Clark RS, Kochanek PM, Kagan VE, Bayir H. 2010b. Alpha-synuclein levels are elevated in cerebrospinal fluid following traumatic brain injury in infants and children: the effect of therapeutic hypothermia. Dev Neurosci 32:385-395.
49. Tajiri N, Acosta SA, Shahaduzzaman M, Ishikawa H, Shinozuka K, Pabon M, Hernandez-Ontiveros D, Kim DW, Metcalf C, Staples M, Dailey T, Vasconcellos J, Franyuti G, Gould L, Patel N, Cooper D, Kaneko Y, Borlongan CV, Bickford PC. 2014. Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats. J Neurosci 34:313-326.
50. Ulusoy A, Di Monte DA. 2013. Alpha-synuclein elevation in human neurodegenerative diseases: Experimental, pathogenetic, and therapeutic implications. Mol Neurobiol 47:484-494.
51. Uryu K1, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH. 2007. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol 208:185-192.
52. Wagner AK, Amin KB, Niyonkuru C, Postal BA, McCullough EH, Ozawa H, Dixon CE, Bayir H, Clark RS, Kochanek PM, Fabio A. 2011. CSF Bcl-2 and cytochrome C temporal profiles in outcome prediction for adults with severe TBI. J Cereb Blood Flow Metab 31:1886-1896.
53. Wakabayashi K, Tanji K, Mori F, Takahashi H. 2007. The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27:494-506.
54. Wan OW, Chung KK. 2012. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS One 7:e38545.
55. Werner C, Engelhard K. 2007. Pathophysiology of traumatic brain injury. Br J Anesth 99:4-9.
56. Wong JC, Hazrati LN. 2013. Parkinson's disease, parkinsonism, and traumatic brain injury. Crit Rev Clin Lab Sci 50:103-106.
57. Xiong Y, Mahmood A, Chopp M. 2013. Animal models of traumatic brain injury. Nat Rev Neurosci 14:128-142.
58. Yu S, Kaneko Y, Bae E, Stahl CE, Wang Y, van Loveren H, Sanberg PR, Borlongan CV. 2009. Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits. Brain Res 1287:157-163.
59. Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA, Uéda K, Chan P. 2004. Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367:34-39.